Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:VNDA
- CUSIP: 92165910
- Web: www.vandapharmaceuticals.com
Capitalization:- Market Cap: $719.97 million
- Outstanding Shares: 44,858,000
Average Prices:- 50 Day Moving Avg: $16.19
- 200 Day Moving Avg: $14.77
- 52 Week Range: $11.58 - $18.00
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -84.47
- P/E Growth: -2.21
Sales & Book Value:- Annual Revenue: $156.2 million
- Price / Sales: 4.61
- Book Value: $2.93 per share
- Price / Book: 5.48
Profitability:- EBIDTA: ($4,150,000.00)
- Net Margins: -6.54%
- Return on Equity: -7.85%
- Return on Assets: -4.90%
Debt:- Current Ratio: 2.31%
- Quick Ratio: 2.30%
Misc:- Average Volume: 463,548 shs.
- Beta: 1.49
- Short Ratio: 4.15
Frequently Asked Questions for Vanda Pharmaceuticals (NASDAQ:VNDA)
What is Vanda Pharmaceuticals' stock symbol?
Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."
How were Vanda Pharmaceuticals' earnings last quarter?
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) posted its earnings results on Wednesday, August, 2nd. The company reported ($0.03) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.18. The firm earned $42.06 million during the quarter, compared to analysts' expectations of $40.31 million. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The company's quarterly revenue was up 16.7% compared to the same quarter last year. During the same period last year, the company posted $0.01 EPS. View Vanda Pharmaceuticals' Earnings History.
When will Vanda Pharmaceuticals make its next earnings announcement?
Where is Vanda Pharmaceuticals' stock going? Where will Vanda Pharmaceuticals' stock price be in 2017?
8 equities research analysts have issued 1-year price objectives for Vanda Pharmaceuticals' shares. Their forecasts range from $18.00 to $24.00. On average, they anticipate Vanda Pharmaceuticals' stock price to reach $21.75 in the next twelve months. View Analyst Ratings for Vanda Pharmaceuticals.
Who are some of Vanda Pharmaceuticals' key competitors?
Some companies that are related to Vanda Pharmaceuticals include MyoKardia (MYOK), Acceleron Pharma (XLRN), Clinigen Group PLC (CLIN), Acorda Therapeutics (ACOR), Neuroderm Ltd (NDRM), Omeros Corporation (OMER), Dermira (DERM), Xencor (XNCR), Retrophin (RTRX), Dynavax Technologies Corporation (DVAX), Sangamo Therapeutics (SGMO), Aduro Biotech (ADRO), Epizyme (EPZM), Amarin Corporation PLC (AMRN), Keryx Biopharmaceuticals (KERX), Five Prime Therapeutics (FPRX), Achaogen (AKAO) and Insmed (INSM).
Who are Vanda Pharmaceuticals' key executives?
Vanda Pharmaceuticals' management team includes the folowing people:
- H. Thomas Watkins, Independent Chairman of the Board
- Mihael Hristos Polymeropoulos M.D., President, Chief Executive Officer, Director
- James Patrick Kelly, Chief Financial Officer, Senior Vice President, Treasurer, Secretary
- Richard L Gulino, Senior Vice President, General Counsel, Secretary
- Gian Piero Reverberi, Senior Vice President, Acting Chief Commercial Officer and European General Manager
- Kenneth M. Bate, Director
- Michael F. Cola, Independent Director
- Richard W. Dugan, Independent Director
- Vincent J. Milano, Independent Director
Who owns Vanda Pharmaceuticals stock?
Vanda Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Palo Alto Investors LLC (9.37%), Vanguard Group Inc. (6.00%), Macquarie Group Ltd. (3.80%), State Street Corp (3.61%), FMR LLC (3.58%) and Renaissance Technologies LLC (2.46%). Company insiders that own Vanda Pharmaceuticals stock include James E Flynn, James Patrick Kelly, Mihael Hristos Polymeropoulos, Paolo Baroldi and Richard L Gulino. View Institutional Ownership Trends for Vanda Pharmaceuticals.
Who sold Vanda Pharmaceuticals stock? Who is selling Vanda Pharmaceuticals stock?
Vanda Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, TIAA CREF Investment Management LLC, Candriam Luxembourg S.C.A., Nexthera Capital LP, Wells Fargo & Company MN, Prudential Financial Inc., Columbus Circle Investors and Pacad Investment Ltd.. Company insiders that have sold Vanda Pharmaceuticals stock in the last year include James E Flynn and Richard L Gulino. View Insider Buying and Selling for Vanda Pharmaceuticals.
Who bought Vanda Pharmaceuticals stock? Who is buying Vanda Pharmaceuticals stock?
Vanda Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, AJO LP, Vanguard Group Inc., Renaissance Technologies LLC, Macquarie Group Ltd., Spark Investment Management LLC, Ameriprise Financial Inc. and Numeric Investors LLC. View Insider Buying and Selling for Vanda Pharmaceuticals.
How do I buy Vanda Pharmaceuticals stock?
Shares of Vanda Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vanda Pharmaceuticals' stock price today?
One share of Vanda Pharmaceuticals stock can currently be purchased for approximately $16.05.
MarketBeat Community Rating for Vanda Pharmaceuticals (NASDAQ VNDA)MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Vanda Pharmaceuticals (NASDAQ:VNDA) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 8 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $21.75 (35.51% upside) |
Analysts' Ratings History for Vanda Pharmaceuticals (NASDAQ:VNDA)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/3/2017 | Piper Jaffray Companies | Set Price Target | Buy | $23.00 | High |  |
| 8/3/2017 | HC Wainwright | Set Price Target | Buy | $18.00 | High | |
| 8/3/2017 | Oppenheimer Holdings, Inc. | Set Price Target | Buy | $21.00 | High | |
| 5/25/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $21.00 | Medium | |
| 4/12/2017 | CIBC | Reiterated Rating | Outperform -> Outperform | $21.00 | Low | |
| 11/9/2016 | Aegis | Initiated Coverage | Buy | $24.00 | N/A | |
| 10/10/2016 | Brean Capital | Set Price Target | Buy | $24.00 | N/A | |
| 8/26/2016 | JMP Securities | Boost Price Target | Market Outperform | $18.00 -> $22.00 | N/A | |
| 3/14/2016 | Canaccord Genuity | Reiterated Rating | Buy | $18.00 | N/A | |
(Data available from 8/17/2015 forward)
Earnings History for Vanda Pharmaceuticals (NASDAQ:VNDA)Earnings History by Quarter for Vanda Pharmaceuticals (NASDAQ VNDA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/31/2017 | | ($0.15) | | | | | N/A | |
| 8/2/2017 | Q2 2017 | ($0.21) | ($0.03) | $40.31 million | $42.06 million | View | Listen | |
| 5/2/2017 | Q1 2017 | ($0.13) | ($0.17) | $38.35 million | $37.42 million | View | Listen | |
| 2/15/2017 | Q416 | ($0.06) | ($0.01) | $39.38 million | $38.24 million | View | Listen | |
| 11/2/2016 | Q316 | ($0.14) | ($0.01) | $38.05 million | $38.48 million | View | Listen | |
| 7/27/2016 | Q216 | ($0.23) | ($0.11) | $36.03 million | $36.02 million | View | Listen | |
| 5/4/2016 | Q116 | ($0.24) | ($0.17) | $32.48 million | $33.30 million | View | Listen | |
| 2/10/2016 | Q415 | ($0.26) | ($0.23) | $31.34 million | $31.85 million | View | Listen | |
| 11/3/2015 | Q315 | ($0.20) | ($0.11) | $28.58 million | $28.34 million | View | Listen | |
| 7/29/2015 | Q2 | ($0.32) | ($0.01) | $24.55 million | $27.60 million | View | Listen | |
| 5/6/2015 | Q1 | ($0.25) | ($0.24) | $20.18 million | $22.20 million | View | Listen | |
| 2/19/2015 | Q4 | $0.56 | ($0.36) | $35.57 million | $15.40 million | View | Listen | |
| 10/27/2014 | Q314 | ($0.39) | ($0.04) | $12.20 million | $14.80 million | View | Listen | |
| 8/7/2014 | Q2 | ($0.70) | ($0.64) | $10.00 million | $10.80 million | View | Listen | |
| 5/8/2014 | Q1 | ($0.29) | ($0.79) | $8.50 million | $9.10 million | View | Listen | |
| 2/13/2014 | Q413 | ($0.20) | ($0.23) | $8.50 million | $8.80 million | View | Listen | |
| 11/7/2013 | Q313 | ($0.30) | ($0.43) | $8.45 million | $8.70 million | View | Listen | |
| 7/31/2013 | Q2 2013 | ($0.22) | ($0.26) | $8.43 million | $8.30 million | View | Listen | |
| 5/9/2013 | Q1 2013 | ($0.25) | ($0.15) | $8.42 million | $8.10 million | View | Listen | |
| 2/12/2013 | Q4 2012 | ($0.22) | ($0.23) | $8.60 million | $7.90 million | View | Listen | |
| 11/7/2012 | Q312 | ($0.22) | ($0.19) | $8.40 million | $8.28 million | View | N/A | |
| 8/2/2012 | | ($0.27) | ($0.28) | | | View | N/A | |
| 5/8/2012 | | ($0.16) | ($0.28) | | | View | N/A | |
| 2/14/2012 | | ($0.19) | ($0.20) | | | View | N/A | |
| 11/4/2011 | | ($0.12) | ($0.11) | | | View | N/A | |
| 8/4/2011 | | ($0.07) | ($0.05) | | | View | N/A | |
| 2/10/2011 | | ($0.02) | $0.08 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)2017 EPS Consensus Estimate: ($0.65)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.18) | ($0.15) | ($0.17) |
| Q2 2017 | 2 | ($0.27) | ($0.20) | ($0.24) |
| Q3 2017 | 2 | ($0.13) | ($0.08) | ($0.11) |
| Q4 2017 | 2 | ($0.18) | ($0.10) | ($0.14) |
(Data provided by Zacks Investment Research)
Dividend History for Vanda Pharmaceuticals (NASDAQ:VNDA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Vanda Pharmaceuticals (NASDAQ:VNDA)Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 90.84%
Insider Trades by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 1/3/2017 | Richard L Gulino | SVP | Sell | 10,900 | $15.51 | $169,059.00 | |
| 9/23/2016 | James E Flynn | Insider | Sell | 1,120,461 | $16.56 | $18,554,834.16 | |
| 9/19/2016 | James E Flynn | Insider | Sell | 547,886 | $15.66 | $8,579,894.76 | |
| 1/4/2016 | James Patrick Kelly | CFO | Sell | 9,564 | $8.96 | $85,693.44 | |
| 1/4/2016 | Mihael Hristos Polymeropoulos | CEO | Sell | 21,353 | $8.96 | $191,322.88 | |
| 1/4/2016 | Paolo Baroldi | SVP | Sell | 12,380 | $8.96 | $110,924.80 | |
| 12/11/2015 | James E Flynn | Insider | Buy | 1,201,364 | $8.38 | $10,067,430.32 | |
| 9/10/2015 | Mihael Hristos Polymeropoulos | CEO | Sell | 131,739 | $12.68 | $1,670,450.52 | |
| 5/22/2015 | Mihael Hristos Polymeropoulos | CEO | Sell | 186,395 | $10.36 | $1,931,052.20 | |
| 3/9/2015 | Richard W Dugan | Director | Sell | 4,804 | $10.69 | $51,354.76 | |
| 12/23/2014 | James E Flynn | Insider | Buy | 162,014 | $14.40 | $2,333,001.60 | |
| 3/14/2014 | Thomas Watkins | Director | Sell | 35,000 | $17.66 | $618,100.00 | |
| 11/21/2013 | Robert Repella | SVP | Sell | 107,500 | $12.03 | $1,293,225.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Vanda Pharmaceuticals (NASDAQ:VNDA)
Latest Headlines for Vanda Pharmaceuticals (NASDAQ:VNDA)
| Source: |
|
| Date | Headline |
|---|
 | Vanda Pharmaceuticals Inc. (VNDA) Expected to Announce Quarterly Sales of $44.50 Million
www.americanbankingnews.com - August 16 at 4:04 AM |
| Vanda Pharmaceuticals Inc. (VNDA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 15 at 12:16 PM |
| Vanda Pharmaceuticals Inc. (VNDA) Downgraded by BidaskClub
www.americanbankingnews.com - August 11 at 7:50 PM |
 | Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : August 9, 2017
finance.yahoo.com - August 10 at 9:29 AM |
| Vanda Pharmaceuticals Inc. Expected to Earn Q3 2017 Earnings of ($0.13) Per Share (NASDAQ:VNDA)
www.americanbankingnews.com - August 7 at 7:12 AM |
| Q3 2017 EPS Estimates for Vanda Pharmaceuticals Inc. Boosted by Analyst (VNDA)
www.americanbankingnews.com - August 7 at 7:12 AM |
 | D.C. biotech is angling for massive market to treat jet lag disorders
www.bizjournals.com - August 5 at 8:16 AM |
| Vanda Pharmaceuticals preps for jet lag study results later this year - Washington Business Journal
www.bizjournals.com - August 5 at 8:16 AM |
| Vanda Pharmaceuticals preps for jet lag study results later this year
finance.yahoo.com - August 5 at 8:16 AM |
| FY2021 EPS Estimates for Vanda Pharmaceuticals Inc. Lifted by Analyst (NASDAQ:VNDA)
www.americanbankingnews.com - August 4 at 8:00 PM |
| Vanda Pharmaceuticals Inc. (VNDA) Issues Quarterly Earnings Results, Beats Estimates By $0.18 EPS
www.americanbankingnews.com - August 3 at 3:58 PM |
 | Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 3 at 8:40 AM |
| Vanda Pharmaceuticals Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 8:40 AM |
| Vanda reports 2Q loss
finance.yahoo.com - August 3 at 8:40 AM |
| Edited Transcript of VNDA earnings conference call or presentation 2-Aug-17 8:30pm GMT
finance.yahoo.com - August 3 at 8:40 AM |
| Critical Comparison: Vanda Pharmaceuticals (VNDA) & bluebird bio (BLUE)
www.americanbankingnews.com - July 28 at 2:30 PM |
| Zacks: Brokerages Anticipate Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to Announce -$0.21 EPS
www.americanbankingnews.com - July 27 at 11:17 AM |
| Vanda Pharmaceuticals: An Early Stage Bioscience Consideration - Seeking Alpha
seekingalpha.com - July 27 at 9:15 AM |
| Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:58 AM |
| Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum™ for the Treatment of Schizophrenia
finance.yahoo.com - July 22 at 10:21 AM |
| Vanda Pharmaceuticals Inc. (VNDA) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 21 at 10:56 AM |
 | Vanda Pharmaceuticals (VNDA) Announces Negative Opinion from EMA on Fanaptum for Treatment of Schizophrenia - StreetInsider.com
www.streetinsider.com - July 21 at 8:28 AM |
 | Vanda Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 2, 2017 - PR Newswire (press release)
www.prnewswire.com - July 19 at 4:09 PM |
| Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Rating Lowered to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - July 18 at 12:14 PM |
| Vanda Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 2, 2017
finance.yahoo.com - July 17 at 10:47 AM |
| Q2 2017 EPS Estimates for Vanda Pharmaceuticals Inc. (VNDA) Lowered by Analyst
www.americanbankingnews.com - July 17 at 7:06 AM |
| The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals
finance.yahoo.com - July 14 at 4:59 PM |
| $40.37 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - July 5 at 11:47 AM |
| Zacks: Analysts Anticipate Vanda Pharmaceuticals Inc. (VNDA) to Announce -$0.23 EPS
www.americanbankingnews.com - July 3 at 10:14 AM |
| Vanda Pharmaceuticals Inc. (VNDA) Coverage Initiated at Piper Jaffray Companies
www.americanbankingnews.com - June 27 at 9:14 AM |
| Vanda Pharmaceuticals Inc. (VNDA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 26 at 10:15 AM |
| Vanda Pharmaceuticals (VNDA) Presents At JMP Securities Life Sciences Conference 2017 - Slideshow
seekingalpha.com - June 22 at 7:37 PM |
| Vanda: Several Catalysts Coming Up - Seeking Alpha
seekingalpha.com - June 22 at 2:35 PM |
| Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : June 21, 2017
finance.yahoo.com - June 22 at 2:35 PM |
| Vanda Pharmaceuticals (VNDA) Worth a Look: Stock Jumps 8%
finance.yahoo.com - June 22 at 2:35 PM |
| Vanda Pharmaceuticals Inc. (VNDA) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - June 14 at 2:18 PM |
| Vanda Pharmaceuticals (VNDA) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 9 at 2:03 AM |
| Vanda Pharmaceuticals Inc. (VNDA) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - June 7 at 8:42 AM |
| Vanda Pharmaceuticals Announces Participation at June 2017 Investor Conferences - PR Newswire (press release)
www.prnewswire.com - June 7 at 8:17 AM |
| -$0.23 EPS Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - June 7 at 8:04 AM |
| Vanda Pharmaceuticals Announces Participation at June 2017 Investor Conferences
finance.yahoo.com - June 6 at 1:50 AM |
| Research Reports Initiation on Biotech Stocks -- Corcept ... - PR Newswire (press release)
www.prnewswire.com - May 30 at 3:26 PM |
| Vanda Pharmaceuticals Inc. (VNDA) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 30 at 11:04 AM |
| Vanda Pharmaceuticals' (VNDA) "Buy" Rating Reaffirmed at Jefferies Group LLC
www.americanbankingnews.com - May 27 at 10:56 AM |
| Vanda Pharmaceuticals Inc. (VNDA) Coverage Initiated at HC Wainwright
www.americanbankingnews.com - May 26 at 12:58 PM |
| Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : May 22, 2017
finance.yahoo.com - May 22 at 7:36 PM |
| Vanda Pharmaceuticals Inc. (VNDA) Upgraded by TheStreet to C-
www.americanbankingnews.com - May 17 at 2:50 PM |
| $40.3 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - May 13 at 9:00 AM |
| Vanda Pharmaceuticals Inc. (VNDA) Expected to Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - May 11 at 10:44 AM |
| Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : May 9, 2017
finance.yahoo.com - May 9 at 9:44 AM |
Vanda Pharmaceuticals (VNDA) Chart for Thursday, August, 17, 2017
